beta-1 adrenergic receptor
ARCA aims to boost participation by easing stringent enrollment criteria in a study investigating Gencaro in heart failure patients with a favorable response genotype.
The FDA has approved a trial investigating bucindolol in approximately 3,200 chronic heart failure patients who have a genotype associated with response to the beta-blocker and mild vasodilator.